Literature DB >> 24418499

Evaluation of commercial herpes simplex virus IgG and IgM enzyme immunoassays.

Kristin Liermann1, Anna Schäfler1, Andreas Henke1, Andreas Sauerbrei2.   

Abstract

Serological methods are used widely for the determination of herpes simplex virus (HSV) IgG and IgM antibodies in virological laboratories. The present study evaluates the automated performance of the Virion\Serion (Würzburg, Germany) and Orgentec (Mainz, Germany) enzyme-linked immunosorbent assays (ELISA) for the determination of HSV type-common and type-specific IgG and IgM antibodies. Two hundred sixty-three sera from HSV-negative children, healthy blood donors as well as patients without and with acute HSV infections were included. The Serion ELISAs classic HSV 1+2, HSV 1 and HSV 2 IgG showed sensitivities between 89.1% and 98.0% and specificities from 82.8% to 100%. Sensitivities of the Orgentec ELISAs Anti-HSV-1 and Anti-HSV-2 IgG were calculated as 91.0-96.0% and 88.5-95.4% accompanied by specificities between 93.1% and 100%. The HSV type-common Serion IgM ELISA revealed also a high sensitivity and specificity. However, the single-type HSV-1 and HSV-2 IgM ELISAs from both companies did not detect reliably HSV-1- and HSV-2-specific IgM antibodies. In conclusion, the automated performance of Serion ELISAs classic HSV 1+2, HSV 1 and HSV 2 IgG as well Orgentec ELISAs Anti-HSV-1 and Anti-HSV-2 IgG provide highly dependable results for identifying HSV-1 and HSV-2 IgG-positive or -negative individuals. While HSV type-common IgM ELISAs can be useful to confirm acute newly acquired HSV infections, the use of single-type IgM ELISAs on the basis of whole-virus antigen is dispensable.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ELISA; Genital herpes; Glycoprotein G; HSV-1; HSV-2; Laboratory diagnostic reagents

Mesh:

Substances:

Year:  2014        PMID: 24418499     DOI: 10.1016/j.jviromet.2014.01.001

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Antibody and Viral Nucleic Acid Testing of Serum and Cerebrospinal Fluid for Diagnosis of Eastern Equine Encephalitis.

Authors:  James A Sherwood; David C Brittain; John J Howard; JoAnne Oliver
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

Review 2.  Herpes Genitalis: Diagnosis, Treatment and Prevention.

Authors:  A Sauerbrei
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10-18       Impact factor: 2.915

3.  Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG.

Authors:  Fernando de Ory; María-Eulalia Guisasola; Pilar Balfagón; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

4.  Maternal Antibodies to Herpes Virus Antigens and Risk of Gastroschisis in Offspring.

Authors:  Martha M Werler; Samantha E Parker; Klaus Hedman; Mika Gissler; Annukka Ritvanen; Heljä-Marja Surcel
Journal:  Am J Epidemiol       Date:  2016-11-17       Impact factor: 4.897

Review 5.  Laboratory Diagnosis of Central Nervous System Infection.

Authors:  Taojun He; Samuel Kaplan; Mini Kamboj; Yi-Wei Tang
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

Review 6.  Optimal management of genital herpes: current perspectives.

Authors:  Andreas Sauerbrei
Journal:  Infect Drug Resist       Date:  2016-06-13       Impact factor: 4.003

7.  Detection of antibody-secreting cells specific for the cytomegalovirus and herpes simplex virus surface antigens.

Authors:  Mira Alt; Jessica Falk; Anna Maria Eis-Hübinger; Barbara Kropff; Christian Sinzger; Adalbert Krawczyk
Journal:  J Immunol Methods       Date:  2018-07-27       Impact factor: 2.303

8.  Investigation of the association between the antibody responses to neurotropic viruses and dementia outcomes in the UK Biobank.

Authors:  Krisztina Mekli; Artitaya Lophatananon; Rachel Cant; Alistair Burns; Curtis B Dobson; Ruth F Itzhaki; Kenneth R Muir
Journal:  PLoS One       Date:  2022-10-12       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.